About
Acrivon develops targeted precision oncology therapies by using its proprietary AP3 platform to match drug mechanisms to the biological drivers of cancer, focusing on kinase inhibitors and DNA damage response pathways, with several clinical-stage drug candidates.
Explore Acrivon's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.